Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption

A STROBE-compliant study

Wenwen Chen, MD\textsuperscript{a,b}, Yanyan Liu, MD\textsuperscript{b}, Longlong Tang, MD\textsuperscript{c}, Zhenshan Li, MD\textsuperscript{a}, Yanlin Liu, MD\textsuperscript{a}, Heqin Dang, MD\textsuperscript{a}\textsuperscript{*}

Abstract
Sacubitril/valsartan (sac/val) was launched in China in 2018; however, the adoption of sac/val in real-world clinical practice has yet to be described.

This study aimed to analyze real-world treatment patterns of sac/val using data from 3 tertiary hospitals in China.

A non-interventional, retrospective cohort study of patients with Heart failure (HF) prescribed sac/val from 3 tertiary hospitals in China between January 1, 2018 and June 30, 2020 was conducted. The analysis included sac/val dose titration patterns and persistence during 6 months post-index.

A total of 267 patients were included, with a mean age of 63.9±13.1 years. At index, 27% of patients were prescribed sac/val 12/13 mg b.i.d., 63.7% were prescribed 24/26 mg b.i.d., 4.5% were prescribed the target dose of 49/51 mg b.i.d., and 4.8% were not prescribed according to the recommended dose. During the 6 months post-index, 8.3% of patients had only 1 dose titration record.

Good therapeutic persistence was observed across sac/val doses, and only 15.7% of patients discontinued sac/val during the 6 months post-index.

In China, the majority of patients prescribed sac/val are not initiated on the recommended dose nor up-titrated according to drug instruction. Notably, good persistence with sac/val is observed in the real-world cohort study.

Abbreviations: HF = heart failure, LVEF = left ventricular ejection fraction, NYHA = New York Heart Association, sac/val = sacubitril/valsartan, SBP = systolic blood pressure.

Keywords: dose titration, heart failure, persistence, prescription, sacubitril/valsartan

1. Introduction
Heart failure (HF) is a major public health challenge owing to its impact on mortality, morbidity, and economic burden.\cite{1-4} The prevalence of HF in China in 2019 was estimated at approximately 1.3%,\cite{5} and hospitalization is a major driver of HF treatment cost, which is consequently associated with substantial costs to the healthcare system.\cite{6} Although the discovery and optimized use of pharmacotherapies that improve outcomes such as those targeting the renin-angiotensin-aldosterone system,\cite{7} the 5-year mortality and rates of hospitalization remain poor.\cite{8} Therefore, identification and development of novel pharmacological therapies remain paramount to improving outcomes in HF.

Sacubitril/valsartan (sac/val), a first-in-class dual action molecule of the neprilysin inhibitor sacubitril and the angiotensin II type 1 receptor blocker valsartan, demonstrated a 20% reduction in the primary outcome of cardiovascular death or HF hospitalization (HR, 0.80; 95% CI, 0.73–0.87) in PARADIGM-HF study.\cite{9} As a result, sac/val was approved by the Food and Drug Administration and European Medicines Agency and received a Class I recommendation in the European and US HF guidelines.\cite{10,11} However, several studies have shown that treatment patterns of sac/val under real-world conditions were different with the PARADIGM-HF study\cite{12-17} which might affect prescription of sac/val in clinical practice.

Sac/val was launched in China in 2018, however, the adoption of sac/val in real-world clinical practice has yet to be described. Therefore, the purpose of this study was to describe prescription patterns of sac/val in clinical practice using data from 3 tertiary hospitals in China. This study also aimed to evaluate possible factors associated to persistence of sac/val after index.
2. Materials and methods

2.1. Study design

We carried out a non-interventional, retrospective cohort study of patients with HF from 3 tertiary hospitals in China. The full study period was between January 1, 2018 and June 30, 2020, giving a minimum of 6 months of follow-up after sac/val initiation.\(^{[18]}\)

2.2. Study population

HF patients aged ≥18 years who were prescribed sac/val at least once between January 1, 2018 and January 30, 2020 were included in the study. For each individual, the index date was defined as the date of their first recorded sac/val prescription.

2.3. Sac/val dose and titration patterns

Sac/val dose and titration patterns were analyzed during the 6 months after index. Key outcomes included individual dose at index and titration patterns during the 6 months after index.

2.4. Sac/val persistence

Sac/val persistence was assessed using the direct-reporting method (by asking the patient, “Are you still persistent with therapy with sac/val?”).\(^{[19]}\) All patients were contacted by telephone during the 6 months after index to determine sac/val persistence.

2.5. Statistical analysis

Continuous variables are expressed as mean± standard deviation if normally distributed or median (inter-quartile range) if not normally distributed. Normality was checked by the Shapiro–Wilk statistic. Categorical data were expressed as numbers and percentages and compared with Pearson’s χ² test or Fisher exact, when appropriate. Continuous variables were compared with Student t test, Mann–Whitney U test, and paired t-test, when appropriate. Univariate and multivariate logistic regression were used to assess predictors of sac/val persistence in the 6 months after initiation. Statistical Significance was considered if \(P\ value <.05\). Statistics were performed using SPSS version 21 (IBM, Chicago, IL).

2.6. Ethics statement

Only aggregated, anonymized patient data were used in these analyses. This study was approved by the Ethics Committee of the Second Affiliated Hospital of Shandong First Medical University, Tengzhou Central People's Hospital, and Xintai People's Hospital.

3. Results

3.1. Baseline patient demographics and characteristics

In total, 267 patients were enrolled into the study between January 1, 2018 and January 30, 2020. The patient demographics and characteristics are shown in Table 1. The mean age of these patients was 63.9 ± 13.1 years and more than two-thirds of the study population (69.7%) were male. The mean systolic blood pressure (SBP) was 120 ± 18 mmHg, and 75.6% of patients were New York Heart Association (NYHA) Class III/IV. The mean left ventricular ejection fraction (LVEF) was 36.7% ± 10.2% in these patients, and the proportion of patients with ejection fraction (EF) ≤40% was 61.4%. Patients in the present study were predominantly male, had a higher LVEF, had a lower SBP, and had a higher NYHA class than those in the PARADIGM-HF trial. The most frequently recorded comorbidities were ischaemic heart disease and hypertension, which were recorded in 69% and 45% of patients, respectively (Table 1). Patients were less likely to have atrial fibrillation, hypertension and diabetes but more likely to have stroke and ischaemic heart disease than patients in PARADIGM-HF study. Use of cardiovascular medications was high: 92.5%, 81.3%, and 89.1% of patients had received prescriptions for aldosterone antagonists, beta-blockers, and loop diuretics, respectively.

3.2. Sac/val dose at index and treatment patterns

At index, 27% of patients were prescribed sac/val 12/13 mg b.i.d., 63.7% were prescribed 24/26 mg b.i.d., 4.5% were prescribed the target dose of 49/51 mg b.i.d., and 4.8% were not prescribed according to the above dose pattern. In total, only 23 patients (8.3%) had 1 dose titration record during the 6 months post-index. Moreover, any titration efforts attempted on these patients was done prior to discharge, and the mean time to dose titration was 6 ± 2 days. Among 254 patients

### Table 1

| Variable                                | Patients in the present study (n = 267) | PARADIGM-HF sac/val arm (n = 4,187) | \(P\) value |
|-----------------------------------------|----------------------------------------|-----------------------------------|-----------|
| Demographics                            |                                        |                                   |           |
| Age, yr                                 | 63.9 ± 13.1                            | 63.8 ± 11.5                       | .891      |
| Male, n (%)                             | 186 (69.7)                             | 3308 (79)                         | <.001     |
| Prior hospitalization for HF, n (%)     | 159 (59.6)                             | 2607 (62.3)                       | .376      |
| Blood pressure                          |                                        |                                   |           |
| SBP, mmHg                               | 120 ± 18                                | 122 ± 15                          | .037      |
| NYHA class, n (%)                       |                                        |                                   | <.001     |
| Class I                                 | 7 (2.6)                                | 180 (4.3)                         |           |
| Class II                                | 50 (18.7)                              | 2998 (71.6)                       |           |
| Class III                               | 104 (38.9)                             | 969 (23.1)                        |           |
| Class IV                                | 96 (36.7)                              | 33 (0.8)                          |           |
| Missing                                 | 8 (3)                                  | 7 (0.2)                           |           |
| Mean LVEF, %                            | 36.7 ± 10.2                            | 29 ± 6.1                          | <.001     |
| LVEF ≤40%, n (%)                        | 164 (61.4)                             | NA                                |           |
| LVEF >40%, n (%)                        | 70 (26.2)                              | NA                                |           |
| LVEF Missing, n (%)                     | 33 (12.4)                              | NA                                |           |
| Co-morbidities, n (%)                   |                                        |                                   |           |
| Atrial fibrillation                     | 67 (25.1)                              | 1517 (36.2)                       | <.001     |
| Ischaemic heart disease                 | 185 (69.3)                             | 1818 (43.4)                       | <.001     |
| Hypertension                            | 122 (45.7)                             | 2969 (70.9)                       | <.001     |
| Diabetes                                | 65 (24.3)                              | 1451 (34.7)                       | .001      |
| Stroke                                  | 33 (12.4)                              | 355 (8.5)                         | .029      |
| Medication use at index, n (%)          |                                        |                                   |           |
| Beta-blocker                            | 217 (81.3)                             | 3899 (93.1)                       | <.001     |
| Aldosterone antagonist                  | 247 (92.5)                             | 2271 (54.2)                       | <.001     |
| Loop diuretics                          | 238 (89.1)                             | 3363 (80.3)                       | <.001     |
| Digoxin                                 | 82 (30.7)                              | NA                                |           |
| Lipid-lowering drugs                    | 186 (69.7)                             | NA                                |           |
| Antiplatelet medications               | 184 (68.9)                             | NA                                |           |

Sac=valsacubitril/valsartan, HF = heart failure, SBP = systolic blood pressure, NYHA = New York Heart Association, LVEF = left ventricular ejection fraction.
prescribed sac/val according to the recommended dose, only 2.5% of patients were up-titrated during this period, and down-titration was observed in 1.5% of patients. Of the patients who were prescribed 12/13 mg b.i.d. or 24/26 mg b.i.d at index, 15.3% and 3.5% were up-titrated, respectively. Of the patients who were prescribed 24/26 mg b.i.d. or 49/51 mg b.i.d. at index, 1.76% and 8.33% were down-titrated, respectively. No titration was observed in 84.72%, 94.71%, and 67% of patients who were prescribed 12/13 mg b.i.d., 24/26 mg b.i.d, and 49/51 mg b.i.d. (Fig. 1).

3.3. Sac/val persistence

Overall, 225 of the 267 patients (84.3%) were persistent with sac/val in the 6 months after index, and only 42 patients (15.7%) discontinued sac/val. The univariate and multivariate predictors of 6-month medication persistence are shown in Table 2. Adjusting for potential confounders, better persistence was observed in patients with LVEF ≤40% and those having prior hospitalization for HF.

4. Discussion

Our study has 4 main findings:

1. real-world patients exhibit baseline characteristics of more pronounced disease severity in comparison with patients in PARADIGM-HF study;
2. 27% of patients received the lowest dose of sac/val (12/13 bid);
3. 87.3% of all patients stay on their initial dose in the 6 months post-index; and
4. the estimated persistence with sac/val at 6 months was high across all doses.

Although sac/val has convincingly proven its benefit in reducing HF hospitalization and cardiovascular mortality in PARADIGM-HF, patients with severe symptomatic HF were underrepresented in this trial.[19,20] Our findings showed that patients prescribed sac/val in real world are more likely to have a higher NYHA classification and a lower baseline LVEF than patients enrolled in the PARADIGM-HF trial, which supported those observations in several recent real-world studies.[13,17,21,22] The present study and the other real-world studies conformably indicate that patients in real-world clinical practice have more severe HF than those enrolled in PARADIGM-HF.[13,17,21,22]

Similar to other real-world studies,[13,17,23,24] the majority of patients (63.7%) were prescribed the sac/val dose of 24/26 mg b.i.d. at index despite this dose being suggested for special populations; those with moderate hepatic impairment, moderate to severe renal impairment, SBP ≥100 mmHg to 110 mmHg, or patients not currently taking or taking a low dose of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.[25,26] Notably, 27% of patients were prescribed sac/val 12/13 mg b.i.d. at index in this study, and so low initial dose has not been reported in previous real-world studies of sac/val.[13,17,23,24] In the present study, reasons for low initial dose of sac/val were hypotension (SBP < 100) (n = 15, 20.8%), older age (age ≥70) (n = 28, 38.9%) and poor heart function (LVEF ≤70) (n = 38, 52.8%). Additionally, 87.3% of patients remained the initial dose during the 6 months post-index. The proportion of patients with no record of dose change in this study is also higher than that in other real-world studies of sac/val.[15,17] Due to the lack of medication prescription experience, physicians are reluctant to titrate up the dose without specific reasons might be a possible cause. Moreover, the effective dose of sac/val in Chinese HF population with smaller body size may be lower than that in Western population.[27] However, because of retrospective study, this viewpoint needs more evidence to prove.

Sac/val persistence (84.3%) at 6 months post-index were found to be high and in line with those observed in other real-world studies.[15,28] Better persistence was observed in patients with LVEF ≤40% and those having prior hospitalization for HF, which could be due to the fact that these patients are with more pronounced disease severity and need long-term treatment to prevent aggravation of HF.

Figure 1. Titration patterns during the 6 months post-index, stratified by sac/val dose at index. sac/val = sacubitril/valsartan.
The main strength of this study lies in that clinical characteristics, prescription patterns, and persistence associated with sac/val adoption in real-world clinical practice in tertiary hospitals in China was described in detail. These findings will offer a larger cardiology audience valuable information when prescribing sac/val. However, several limitations should be mentioned. First, the overall number of patients in this study is relatively small. Second, the data source includes patients in 3 hospitals in China, and findings in other populations may be different. Third, due to the unavailability of enough data on clinical parameters such as NYHA class, LVEF and eGFR, statistical methods such as logistic regression could not be performed to further explore the potential associations between baseline parameters and persistence. Finally, if costs may have influenced prescription of sac/val was not analyzed in the present study.

### Table 2

| Demographics                                    | Continuation (n=225) | Discontinuation (n=42) | Crude P value | Adjusted P value |
|-------------------------------------------------|----------------------|------------------------|---------------|------------------|
| Age, yr                                         | 63.7±13.1            | 65.4±13.1              | .439          | .254             |
| Male, n (%)                                      | 161 (71.6)           | 25 (59.5)              | .119          | .252             |
| Prior hospitalization for HF, n (%)             | 142 (63.1)           | 17 (40.5)              | .006          | .003             |
| Blood pressure                                  |                      |                        |               |                  |
| SBP, mmHg                                       | 120.6±17.8           | 122.8±18.6             | .462          | .281             |
| NYHA classification, n (%)                      |                      |                        |               |                  |
| Class I/II                                      | 47 (20.9)            | 10 (23.8)              | .688          | NA               |
| Class III/IV                                    | 171 (76.0)           | 31 (73.8)              | .001          | .009             |
| LVEF classification, n (%)                      |                      |                        |               |                  |
| LVEF <40%                                       | 157 (69.8)           | 6 (14.3)               | .392          |                  |
| LVEF >40%                                       | 54 (24.0)            | 17 (40.5)              | .325          |                  |
| Co-morbidities, n (%)                           |                      |                        |               |                  |
| Atrial fibrillation                             | 57 (25.3)            | 10 (23.8)              | .325          |                  |
| Ischaemic heart disease                         | 157 (69.8)           | 28 (66.7)              | .677          |                  |
| Hypertension                                    | 108 (48.0)           | 14 (33.3)              | .057          |                  |
| Diabetes                                        | 55 (24.4)            | 14 (33.3)              | .716          |                  |
| Stroke                                          | 27 (12.0)            | 6 (14.3)               | .329          |                  |
| Medication use at index, n (%)                  |                      |                        |               |                  |
| Beta-blocker                                    | 186 (82.7)           | 31 (73.8)              | .118          |                  |
| Aldosterone antagonist                          | 208 (92.4)           | 39 (92.9)              | .187          |                  |
| Loop diuretics                                  | 202 (89.8)           | 36 (85.7)              | .292          |                  |
| Digoxin                                         | 68 (30.2)            | 14 (33.3)              | .518          |                  |
| Lipid-lowering drugs                            | 158 (70.2)           | 28 (66.7)              | .655          |                  |
| Antiplalet medications                          | 158 (70.2)           | 26 (61.9)              | .105          |                  |

Sac/val = sacubitril/valsartan, HF = heart failure, SBP = systolic blood pressure, NYHA = New York Heart Association, LVEF = left ventricular ejection fraction.

**References**

[1] Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63:1123–33.

[2] Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016;13:368–78.

[3] Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7–11.

[4] Shafee AA, Tan YP, Ng CH. Systematic review of economic burden of heart failure. Heart Fail Rev 2018;23:131–45.

[5] Hao G, Wang X, Chen Z, et al. Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey, 2012-2015. Eur J Heart Fail 2019;21:1329–37.

[6] Huang J, Yin H, Zhang M, et al. Understanding the economic burden of heart failure in China: impact on disease management and resource utilization. J Med Econ 2017;20:549–53.

[7] Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov 2007;6:127–39.

[8] Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation 2020;141:e139–596.

[9] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.

[10] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force

---

The univariate and multivariate analyses of predictors of 6-month medication persistence.

**5. Conclusion**

In this multi-center cohort study, patients exhibit baseline characteristics of more pronounced disease severity. Twenty seven percentages of patients are initially prescribed the lowest dose of sac/val (12/13 mg b.i.d.) and 87.3% of all patients stay on their initial dose in the 6 months post-index. Medication persistence during 6 months post-index were high. Further research is required to explore the reasons for the lack of up-titration, and educational efforts to promote up-titration should be intensified.

**Author contributions**

**Conceptualization:** Wenwen Chen, Heqin Dang.

**Data curation:** Yanyan Liu, Longlong Tang, Zhenshan LI.

**Formal analysis:** Wenwen Chen.

**Funding acquisition:** Wenwen Chen.

**Investigation:** Wenwen Chen.

**Methodology:** Wenwen Chen.

**Supervision:** Yanlin Liu, Heqin Dang.

**Writing – original draft:** Wenwen Chen.

**Writing – review & editing:** Wenwen Chen.
for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975.

[11] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart failure society of America. J Am Coll Cardiol 2017;70:776–803.

[12] Wachter R, Viriato D, Klebs S, et al. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany. Postgrad Med 2018;130:308–16.

[13] Martens P, Beliën H, Dupont M, et al. Insights into implementation of sacubitril/valsartan into clinical practice. ESC Heart Fail 2018;5:275–83.

[14] DeVore AD, Hill CL, Thomas L, et al. Patient, provider, and practice characteristics associated with sacubitril/valsartan use in the United States. Circ Heart Fail 2018;11:e005400.

[15] Wachter R, Fonseca AF, Balas B, et al. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail 2019;21:588–97.

[16] Fu M, Vedin O, Svennblad B, et al. Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. ESC Heart Fail 2020;7:3633–43.

[17] Wachter R, Klebs S, Balas B, et al. Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany. ESC Heart Fail 2020;7:2318–30.

[18] Chang HY, Chen KC, Fong MC, et al. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management. J Cardiol 2020;75:233–41.

[19] Fanaroff AC, Peterson ED, Kaltenbach LA, et al. Agreement and accuracy of medication persistence identified by patient self-report vs pharmacy fill: a secondary analysis of the cluster randomized ARTEMIS trial. JAMA Cardiol 2020;5:532–9.

[20] Yandrapalli S, Aronow WS, Mondal P, et al. Limitations of sacubitril/valsartan in the management of heart failure. Am J Ther 2017;24:e234–9.

[21] Savarese G, Hage C, Benson L, et al. Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish heart failure registry. J Intern Med 2020;289:369–84.

[22] Dashwood A, Vale C, Laher S, et al. Impact of patient and model of care factors on titration and tolerability of sacubitril/valsartan: an early Australian real-world experience. Heart Lung Circ 2020;29:1688–95.

[23] Martens P, Beliën H, Dupont M, et al. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther 2018;36:e12435.

[24] Kennedy C, Smith A, Doran S, et al. Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system. Br J Clin Pharmacol 2020;87:406–13.

[25] Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676–83.

[26] Mišić N, Milosević N, Golocorbin Kon S, et al. Warfarin interactions with medicinal herbs. Nat Prod Commun 2014;9:1211–6.

[27] Hsiao FC, Wang CL, Chang PC, et al. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience from Taiwan. J Cardiovasc Pharmacol Ther 2019;25:152–7.

[28] Sangaralingham LR, Sangaralingham SJ, Shah ND, et al. Adoption of sacubitril/valsartan for the management of patients with heart failure. Circ Heart Fail 2018;11:e004302.